Jean-Mathieu Beauregard
Jean-Mathieu Beauregard
Associate Professor of Nuclear Medicine, Université Laval
Verified email at - Homepage
Cited by
Cited by
Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
JM Beauregard, MS Hofman, JM Pereira, P Eu, RJ Hicks
Cancer Imaging 11 (1), 56-66, 2011
The tumour sink effect on the biodistribution of 68 Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
JM Beauregard, MS Hofman, G Kong, RJ Hicks
European journal of nuclear medicine and molecular imaging 39 (1), 50-56, 2012
68Ga PET/CT Ventilation-Perfusion Imaging for Pulmonary Embolism: A Pilot Study with Comparison to Conventional Scintigraphy
MS Hofman, JM Beauregard, TW Barber, OC Neels, P Eu, RJ Hicks
The Journal of Nuclear Medicine 52 (10), 1513, 2011
Pilot comparison of 18F‐fluorocholine and 18F‐fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer
JM Beauregard, SG Williams, TR DeGrado, P Roselt, RJ Hicks
Journal of medical imaging and radiation oncology 54 (4), 325-332, 2010
An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging
PA Jackson, JM Beauregard, MS Hofman, T Kron, A Hogg, RJ Hicks
Medical physics 40 (11), 112503, 2013
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study
M Del Prete, FA Buteau, JM Beauregard
European journal of nuclear medicine and molecular imaging 44 (9), 1490-1500, 2017
Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non–small cell lung cancer
C Lasnon, RJ Hicks, JM Beauregard, A Milner, M Paciencia, AV Guizard, ...
Clinical nuclear medicine 37 (10), 971-976, 2012
Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers
MR Bensaïdane, JM Beauregard, S Poulin, FA Buteau, J Guimond, ...
Journal of Alzheimer's Disease 52 (4), 1251-1262, 2016
Accuracy of 177 Lu activity quantification in SPECT imaging: a phantom study
CF Uribe, PL Esquinas, J Tanguay, M Gonzalez, E Gaudin, ...
EJNMMI physics 4 (1), 1-20, 2017
Assessment of human biodistribution and dosimetry of 4-fluoro-11β-methoxy-16α-18F-fluoroestradiol using serial whole-body PET/CT
JM Beauregard, É Croteau, N Ahmed, JE van Lier, F Bénard
Journal of Nuclear Medicine 50 (1), 100-107, 2009
FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy
JM Beauregard, AC Blouin, V Fradet, A Caron, Y Fradet, C Lemay, ...
Cancer Imaging 15 (1), 1-10, 2015
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
M Del Prete, FA Buteau, F Arsenault, N Saighi, LO Bouchard, A Beaulieu, ...
European journal of nuclear medicine and molecular imaging 46 (3), 728-742, 2019
High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications
N Aide, C Desmonts, JM Beauregard, T Beyer, K Kinross, P Roselt, ...
European journal of nuclear medicine and molecular imaging 37 (5), 991-1001, 2010
Rapid blood clearance and lack of long-term renal toxicity of 177 Lu-DOTATATE enables shortening of renoprotective amino acid infusion
R Kashyap, P Jackson, MS Hofman, P Eu, JM Beauregard, D Zannino, ...
European journal of nuclear medicine and molecular imaging 40 (12), 1853-1860, 2013
[18 F] Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour …
F Bénard, N Ahmed, JM Beauregard, J Rousseau, A Aliaga, C Dubuc, ...
European journal of nuclear medicine and molecular imaging 35 (8), 1473-1479, 2008
Determination of gamma camera calibration factors for quantitation of therapeutic radioisotopes
W Zhao, PL Esquinas, X Hou, CF Uribe, M Gonzalez, JM Beauregard, ...
EJNMMI physics 5 (1), 1-16, 2018
Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
NK Purohit, RG Shah, S Adant, M Hoepfner, GM Shah, JM Beauregard
Oncotarget 9 (37), 24693, 2018
Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177 Lu-octreotate PRRT
M Del Prete, F Arsenault, N Saighi, W Zhao, FA Buteau, A Celler, ...
EJNMMI physics 5 (1), 1-20, 2018
Metabolic imaging of prostate cancer reveals intrapatient intermetastasis response heterogeneity to systemic therapy
F Morin, JM Beauregard, M Bergeron, MN Makao, L Lacombe, V Fradet, ...
European urology focus 3 (6), 639-642, 2017
Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8–10 Prostate Cancers …
E Lavallée, M Bergeron, FA Buteau, AC Blouin, N Duchesnay, T Dujardin, ...
European urology focus 5 (6), 998-1006, 2019
The system can't perform the operation now. Try again later.
Articles 1–20